Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 8/20 | 1.00 |
| ▸ | ITPR2 | Q14571 | 4/20 | 1.00 |
| ▸ | ITPR1 | Q14643 | 4/20 | 1.00 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.84 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.75 |
| ▸ | AKT1 | P31749 | 1/20 | 0.75 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9091859 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL9093199 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL9094714 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL2510044 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL8994052 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL9091912 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL405897 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL8775574 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL9387601 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL15067019 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023180457-A1 | SYNTHETIC GLYCEROPHOSPHOLIPIDS COMPRISING AT LEAST ONE REACTIVE FUNCTION, PROCESS FOR PREPARING SAME AND USES THEREOF IN DIFFERENT APPLICATIONS | UNIVERSITE DE ROUEN-NORMANDIE (FR) | 2023-09-28 | — | — | WO | claimed |
| US-20210106681-A1 | ORGANICALLY MODIFIED MINERAL MICRO-PARTICLES, METHODS OF PREPARING THE SAME AND USES THEREOF | CRODA INTERNATIONAL PLC (GB) | 2021-04-15 | — | — | US | claimed |
| EP-3781517-A1 | ORGANICALLY MODIFIED MINERAL MICRO-PARTICLES, METHODS OF PREPARING THE SAME AND USES THEREOF | Croda International PLC (GB) | 2021-02-24 | — | — | EP | claimed |
| WO-2019201710-A1 | ORGANICALLY MODIFIED MINERAL MICRO-PARTICLES, METHODS OF PREPARING THE SAME AND USES THEREOF | CRODA DENMARK A/S (DK) | 2019-10-24 | — | — | WO | claimed |
| EP-3556728-A1 | ORGANICALLY MODIFIED MINERAL MICRO-PARTICLES, METHODS OF PREPARING THE SAME AND USES THEREOF | Croda Denmark A/S (SE) | 2019-10-23 | — | — | EP | claimed |
| CN-101614970-B | Photoresist cleaning agent composition | ANJI MICROELECTRONICS CO LTD | 2012-12-19 | — | — | CN | claimed |
| CN-101686986-A | Cyclitols and derivatives thereof and their therapeutic use | NORMOXYS INC | 2010-03-31 | — | — | CN | claimed |
| CN-101614970-A | A kind of photoresist cleansing composition | ANJI MICROELECTRONICS CO LTD | 2009-12-30 | — | — | CN | claimed |
| EP-2111226-A2 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | Normoxys, Inc. (US) | 2009-10-28 | — | — | EP | claimed |
| US-20080200437-A1 | Polyphosphorylated inositol derivatives; allosteric effectors, cell signaling molecule analogs; hypoxia related diseases | UNIVERSITE DE STRASBOURG (FR) | 2008-08-21 | — | — | US | claimed |
| WO-2008082658-A2 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NORMOXYS, INC. (US) | 2008-07-10 | — | — | WO | claimed |
| EP-4370667-A1 | PHYTASE VARIANTS | AB Enzymes Oy (FI) | 2024-05-22 | — | — | EP | disclosed |
| EP-4370669-A1 | PHYTASE VARIANTS | AB Enzymes Oy (FI) | 2024-05-22 | — | — | EP | disclosed |
| EP-4370670-A1 | PHYTASE VARIANTS WITH IMPROVED STABILITY AND IP4 ACTIVITY | AB Enzymes Oy (FI) | 2024-05-22 | — | — | EP | disclosed |
| US-20240115595-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | TEAM MEDICAL, LLC (US) | 2024-04-11 | — | — | US | disclosed |
| WO-1990002201-A1 | METHOD AND KIT FOR DIAGNOSIS OF MALIGNANT HYPERPYREXIA | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1990-03-08 | — | — | WO | disclosed |
| US-4873355-A | Process for regioselectively preparing phosphorylated inositols and other cyclitols | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-10-10 | — | — | US | disclosed |
| US-4839466-A | Insulin activity messengers | THE ROCKEFELLER UNIVERSITY (US) | 1989-06-13 | — | — | US | disclosed |
| EP-0245956-A2 | Insulin activity messengers, their precursors and uses thereof | ROCKEFELLER UNIVERSITY (US) | 1987-11-19 | — | — | EP | disclosed |
| EP-0233403-A1 | Photo-labile protecting agents and method | MEDICAL RESEARCH COUNCIL (GB) | 1987-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200437-A1 | Polyphosphorylated inositol derivatives; allosteric effectors, cell signaling molecule analogs; hypoxia related diseases | PPIP5K2, IP6K1, IP6K3 | ITPR3 23/4885ITPR2 20/4885ITPR1 13/4885 |
| US-20210106681-A1 | ORGANICALLY MODIFIED MINERAL MICRO-PARTICLES, METHODS OF PREPARING THE SAME AND USES THEREOF | ACP3, SOST, ALPP | ITPR3 372/4885ITPR2 470/4885ITPR1 414/4885 |
| US-20240115595-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | RBM22, HNRNPUL2, HNRNPUL1 | ITPR3 3547/4885ITPR2 3622/4885ITPR1 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.